Amoxicillin effectiveness

The antibacterial effect of AMX + MET and PV + MET combinations on biofilms was obvious by CLSM imaging, as an increased proportion of red bacterial?like structures were observed throughout the biofilms' three?dimensional structure, in contrast to the few remaining green structures, located mainly at the bottom of the biofilms (Figure 4c,d). A biofilm amoxicillin 500 tablet consisting of three bacterial strains, one known as intermediate colonizer and two as late colonizers in subgingival plaque, was developed in this study.

The two late colonizers are periodontal pathogens commonly targeted by systemic antibiotic treatment adjunct to mechanical therapy in periodontal disease (Slots, Research, & Therapy, 2004 ). In our study, the combination AMX + MET was highly effective against F .

gingivalis , as previously reported in other in vivo and in vitro studies (Astasov?Frauenhoffer et al., 2014 ; Sbordone, Barone, Ramaglia, Ciaglia, & Iacono, 1995 ; Soares et al., 2015 ).

These two anaerobic bacteria may be killed by MET treatment only, in contrast to A .

actinomycetemcomitans that cannot be completely eliminated by MET alone. The exposure of our 3 days biofilm to MET alone resulted in a similar reduction of A .

actinomycetemcomitans but incomplete elimination of the other two species, as live CFU of F . gingivalis could be retrieved from biofilms treated with MET alone in low concentration (results not shown).

AMX + MET treatment administrated systemically, in individuals who continue to experience loss of periodontal attachment following mechanical debridement, is effective particularly in cases where A . The antibiotic combination eliminates or markedly suppresses the periodontal pathogens that remain after subgingival periodontal instrumentation to a level manageable by the host organism, supporting the host defense in overcoming periodontal infections and reducing the risk for recurrent disease progression (Slots et al., 2004 ). Infections caused by biofilms are difficult to treat as bacteria in biofilms are 100 to 1,000 times more resistant to antimicrobials compared to the same type of bacteria in a planktonic state (Ceri et al., 1999 ; Hoiby et al., 2011 ; Olson, Ceri, Morck, Buret, & Read, 2002 ).

The biofilms thickness increases with the incubation time, containing a higher number of bacteria when reaching the mature state, at 72 hr in our work, as demonstrated in other in vitro studies (Ali Mohammed et al., 2013 ; Sanchez et al., 2011 ).

The antibiotics might not penetrate the deeper layers of the biofilm and thus may not reach bacteria protected in this environment.

The antibiotic concentrations used in this study were very high compared to antibiotic concentration that may be detected in gingival crevicular fluid (Giedrys?Leeper, Selipsky, & Williams, 1985 ; Shaddox & Walker, 2009 ; Tenenbaum, Jehl, Gallion, &

Dahan

This might be explained by the short exposure time to antibiotics that did not fully affect A .

actinomycetemcomitans , which is more slowly growing.

It is also possible that in our model, the nutrients are quickly consumed by the two other species, more rapidly growing, resulting in stationary phase?like dormant A . It is known that antibiotics affect growing cells, thus they are less efficient on bacteria found in a low metabolic activity located in nutrient?deficient areas in biofilm (Olsen, 2015 ). Another in vitro study showed that the susceptibility of A . actinomycetemcomitans in biofilm to six different antibiotics decreases as the biofilm matures (Takahashi, Ishihara, Kato, & Okuda, 2007 ).

actinomycetemcomitans resistant to AMX and MET collected from periodontal patients have previously been reported (Eick, Pfister, & Straube, 1999 ; Rams, Degener, & van Winkelhoff, 2014b ).

Because bacterial pathogens resistant both to AMX and MET were found in relatively low frequency (Al?Haroni, Skaug, & Al?Hebshi, 2006 ; Rams et al., 2014b ; Rams, Degener, & van Winkelhoff, 2014a ), the combination of MET with AMX was recommended rather than using either one alone in order to slow the incidence of developing resistance to MET (Rams et al., 2014a , 2014b ).

A multitude of studies have demonstrated clinical effect of administration of the AMX + MET in combination (Sgolastra, Gatto, et al., 2012 ; Sgolastra, Petrucci, et al., 2012 ; Zandbergen, Slot, Cobb, & Van der Weijden, 2013 ).

Furthermore, synergistic interactions of AMX and MET on an in vitro multispecies biofilm (Soares et al., 2015 ) as well as for both combinations, AMX or PV and MET by Etest (Baumgartner & Xia, 2003 ), have been reported. Pavicic, van Winkelhoff, and de Graaff, 1991 found PG + MET to act synergistically against A . actinomycetemcomitans in vitro using an agar dilution method and checkerboard titrations. Others found synergy between AMX and MET only on a few of the tested A . nucleatum strains (Kulik Kunz, Lenkeit, Waltimo, Weiger, & Walter, 2014 ). In our

study

species

The combination PV + MET seemed to be dose?dependent, as exposure of the biofilms to a three times lower antibiotic concentration resulted in one log higher amount of live CFU retrieved.

However, these results should be interpreted with caution, because in our study, the antibiotic concentrations were high, combined with a short exposure time.

It is timely to recall that although even the commensal bacteria in dental biofilm may cause oral pathology, the aim for periodontal treatment is not a complete elimination of resident periodontal species, but to obtain a microbial profile compatible with health by reducing the proportion of pathogenic species (Marsh, Head, & Devine, 2015 ). A controlled homeostatic immune?inflammatory state is normal in healthy gingiva, the problems arise when dysbiosis develops with a disturbance in the balance between the host and the microbiota in the biofilm (Lamont & Hajishengallis, 2015 ).

In this study, CHX 0.2% was used as a positive control.

The plaque inhibiting effect and antibacterial properties of chlorhexidine are well documented in vivo and in vitro (Addy, 1986 ; Schiott et al., 1970 ). CHX has the ability to penetrate biofilms and having bactericidal effect, acting inside the biofilm (Shapiro, Giertsen, & Guggenheim, 2002 ).

We have used this concentration because with regard to effects on plaque, several reports have demonstrated a significantly better plaque inhibiting effect of 0.2% CHX than 0.12% CHX (Berchier, Slot, & Van der Weijden, 2010 ; Haydari et al., 2017 ). However, Soares et al., 2014 found that CHX 0.12% decreased the metabolic activity of the biofilms by approximately 95% and suggested it to be appropriate as a positive control.

Regarding clinical effects, most studies do not find statistical significant differences in effect on gingivitis between the concentrations 0.2% and 0.12% (Haydari et al., 2017 ). To our knowledge, no studies have compared the two CHX concentrations and evaluated the probing pocket depth and/or the periodontal attachment level.

Concluding, in this in vitro biofilm model, the replacement of AMX with PV at the same concentration, in combination with MET, resulted in similar effect on bacterial viability, by eliminating F .

The option of using PV + MET instead of AMX + MET

deserves

Listing a study does not mean it has been evaluated by the U.S.

Know the risks and potential benefits of clinical studies and talk to your health care provider before participating.

Study Details Tabular View No Results Posted Disclaimer How to Read a Study Record.

Condition or disease Intervention/treatment Phase COVID-19 Pneumonia Combination Product: Azithromycin with amoxicillin/clavulanate Drug: amoxicillin/clavulanate Phase 3.

Layout table for study information Study Type : Interventional (Clinical Trial) Estimated Enrollment : 104 participants Allocation: Randomized Intervention Model: Parallel Assignment Masking: None (Open Label) Primary Purpose: Treatment Official Title: Azithromycin With Amoxicillin/Clavulanate Versus Amoxicillin/Clavulanate Alone in COVID-19 Patients With Pneumonia and Hospitalized in a Non-intensive Care Unit Ward (AziA): a Superiority Open-label Randomized Controlled Trial Estimated Study Start Date : April 30, 2020 Estimated Primary Completion Date : July 30, 2020 Estimated Study Completion Date : July 30, 2020. Choosing to participate in a study is an important personal decision.

Talk with your doctor and family members or friends about deciding to join a study.

To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below.

For general information, Learn About Clinical Studies. Layout table for eligibility information Ages Eligible for Study: 18 Years to 99 Years (Adult, Older Adult) Sexes Eligible for Study: All Accepts Healthy Volunteers: No. Adult ? 18 ans, Patient with positive SARS-CoV-2 RT-PCR on nasopharyngeal sample at randomization or within the previous 48 hours, Patient with pneumonia diagnosed by thorax CT-scan or echography, Patient able to take per os medication, Written and signed consent of the patient, Patients affiliated with or benefitting from a social security scheme.

Patient hospitalized in intensive care unit, Patient who received more than 24 hours of antibiotic treatment for the ongoing episode, Chronic renal failure with a Glomerular Filtration Rate.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor. Michael Stewart, Reviewed by Sid Dajani | Last edited 23 Apr 2019 | Certified by The Information Standard.

Make sure you tell your doctor if you are allergic to penicillin. Amoxicillin is a type of penicillin - do not take it if you are allergic to penicillin.

Space your doses out evenly over the day and complete the full course of the antibiotic, even if you feel your infection has cleared up. You can take amoxicillin either before or after food.

If you have an allergic reaction (such as any swelling around your mouth, any difficulties breathing or a red rash) contact a doctor for advice straightaway. Before taking amoxicillin How to take amoxicillin Getting the most from your treatment Amoxicillin side-effects How to store amoxicillin Important information about all medicines. Type of medicine A penicillin antibiotic Used for Infections (in adults and children) Also called Amoxil® Available as Capsules, oral liquid medicine, sachets and injection. Amoxicillin is given to treat a bacterial infection.

It is mainly prescribed for sinus and chest infections, urine infections, ear infections, and some dental infections. You may also be prescribed it to prevent an infection from occurring if you are at particular risk of getting an infection. Amoxicillin is a penicillin antibiotic which treats infection by killing the germs (bacteria) responsible for the infection. Coronavirus: how quickly do COVID-19 symptoms develop and how long do they last? Coronavirus: what are asymptomatic and mild COVID-19?

Coronavirus: what are moderate, severe and critical COVID-19?